Diamond Ranch Foods (PLPL) 0.5900 $PLPL
Plandai Biotechnology expects up to USD2.5m grant from South African Department of Trade and Industry
M2 - Mon May 05, 7:49AM CDT
Botanical extracts company Plandai Biotechnology (OTCQB
LPL) said on Friday that it expects to receive a grant in the range of USD1.3m to USD2.5m from the South African Department of Trade and Industry (DTI).
Plandai Biotechnology up for $2.5 Million Grant in Continued Support From South African Government
Marketwire - Fri May 02, 8:02AM CDT
Plandai Biotechnology (OTCQB: PLPL) could soon receive another injection of money from the South African government, and this time it's in the form of a South African Department of Trade and Industry (DTI) grant of between $1.3 - $2.5 million. Plandai originally received $13 million in a government backed loan from the Land and Agriculture Bank, and now the company is eligible for the DTI grant which it has filed the paperwork to be awarded. As Plandai officially opens its production facility in South Africa, the government there remains among the most confident in the company's mission.
Plandai Biotechnology, Inc. Files 10-K/A to Include Re-Audited Financial Statements For Prior Two Years
Marketwire - Thu May 01, 8:03AM CDT
Plandai Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced that on April 29, 2014, the Company filed an amended Form 10-K, which includes the re-audited financial statements for the fiscal years ended June 30, 2012 and 2013. The Company voluntarily elected to re-audit the prior two years in response to the Public Company Accounting Oversight Board ("PCAOB"
revocation of the registration of the Company's prior auditor, Patrick Rodgers, CPA. This revocation did not result from any work performed by Mr. Rogers on behalf of Plandai. On January 22, 2014, Plandai accepted the resignation of Patrick Rodgers from his engagement to be the independent certifying accountant and appointed Terry L. Johnson, CPA, as the Company's independent accountant.
Plandai Biotechnology Recruiting Now for Human Clinical Trials to Begin in May
Marketwire - Wed Apr 30, 8:04AM CDT
Plandai Biotechnology (OTCQB: PLPL) has been given the go-ahead to conduct human clinical trials in a 3-month study that will compare the oral bioavailability in the company's Phytofare(TM) Catechin Complex to green tea extracts. In this study, to be conducted at the North West University in Potchefstroom, South Africa, Plandai's 2 technologies, hydrodynamic sheering and Pheroid(R) entrapment, will be put to the test versus a product that hasn't undergone these processes.
Plandai Biotechnology, Inc. Petitions South Africa Department of Health for License to Conduct Cannabis Research
Marketwire - Mon Apr 28, 7:50AM CDT
Plandai Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced it has filed a petition with the Attorney General from the South African Department of Health to obtain a license permitting the company to commence clinical research on the therapeutic and medicinal benefits of cannabis. The petition was made pursuant to Section 22A (9) of the Medicines and Related Substances Act No. 101 of 1965, which provides for pharmaceutical research with cannabis.
OncoSec Medical Appoints New Executive Director of Research and Development
ACCESSWIRE - Tue Apr 22, 10:09AM CDT
OncoSec Medical Inc.'s (OTCQB: ONCS) share volume was strong Apr. 21 with 2,910,820 shares changing hands.
Cannabis Sector Appears To Stabilize With New Advancements - Company Enters JV for 70 Acre Hemp Farm
PR Newswire - Tue Apr 22, 8:02AM CDT
Marijuana companies acquire resources with expansion in sight: Polaris International Holdings, Inc. (OTC: PIHN), Tranzbyte Corporation (OTC: ERBB), Planda (OTC: PLPL), Nuvilex, Inc. (OTC: NVLX), Latteno Food Corp. (OTC: LATF) and MediSwipe, Inc. (OTC: MWIP)
Plandai Biotechnology to begin human bioavailability study of Phytofare against green tea extract in South Africa
M2 - Tue Apr 15, 4:38AM CDT
Plant extracts company Plandai Biotechnology (OTCQBLPL) disclosed on Monday the receipt of approval to begin a human clinical trial to test the oral bioavailability of its Phytofare Catechin Complex in North West University, Potchefstroom, South Africa.
Plandai Biotechnology, Inc. Announces Commencement of Human Bioavailability Study
Marketwire - Mon Apr 14, 10:30AM CDT
Plandai Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced that it has received approval from the Ethics Committee at North West University in Potchefstroom, South Africa to commence a human clinical trial to test the oral bioavailability of its Phytofare(TM) Catechin Complex.
Plandai Biotechnology's Cannabis Extracts Could Further Shape Marijuana Debate
Marketwire - Fri Apr 11, 8:01AM CDT
Plandai Biotechnology (OTCQB: PLPL) has a deal in place to brand and market its future cannabis extracts under the Diego Pellicer Gold label, and it could be those extracts and the company's work with cannabinoids that help shape public opinion in favor of using the drug medicinally. A Pew Research Center survey released last week found that 75 percent of Americans say they feel the legal sale and use of marijuana is inevitable whether they support it or not. While support for marijuana grows, Plandai and its extracts could go a long way toward changing the minds of the drug's opponents.
Plandai Biotechnology, Inc. Qualifies for Grant From South African Department of Trade & Industry
Marketwire - Tue Apr 08, 8:10AM CDT
Plandai Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced that it has qualified for and submitted the necessary paperwork to receive a grant from the South African Department of Trade and Industry (DTI). DTI grants are awarded based on qualifications relating to capital investment in new industry. The Company's extraction and processing factory in the Mpumalanga province in northern South Africa is considered a qualifying facility. DTI representatives will be touring the facility in the first week of May.
Plandai Biotechnology Closer to Unzipping the Magic of Phytofare in New Facility
Marketwire - Fri Apr 04, 7:30AM CDT
Plandai Biotechnology, Inc. (OTCQB: PLPL) welcomes the month of April with a brand new state of the art production facility that is due to be fully operational sometime this month. Plandai recently finished the all-important Stage 2 on the Senteeko Tea Estate in South Africa. It's this section of the factory that CEO Roger Duffield says "the magic of Phytofare" takes place. Plandai will make its money and its mark in the biotechnology sector here as it's where the proprietary hydrodynamic sheering process will takes place.
Plandai Biotechnology, Inc. Commissions Stage 2 of Senteeko Phytofare Factory
Marketwire - Tue Apr 01, 8:03AM CDT
Plandai Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced that it has completed and successfully optimized Stage 2 of its state-of-the-art production facility on the Senteeko Tea Estate in South Africa. Section 2 is the critical stage of the factory's operations as it is in this section that the hydrodynamic sheering process takes place.
Confidential LOI Executed for Unprecedented 'Marijuana Index Fund' - Possible Retracement as The Marijuana Index Dips to $17.95 - 175,000 Jobs Added in February Per US Department of Labor
ACCESSWIRE - Mon Mar 31, 8:09PM CDT
March 31, 2014 / The Marijuana Index - the first and only equity tracking index for marijuana stocks, cannabis stocks, and hemp stocks featuring dynamic financial content, charts, and centralized press for public companies - experienced several significant (positive) events during an otherwise turbulent month (beware the Ides of March, indeed).
Plandai Biotechnology "Waiver" Could Dramatically Expedite Medical Marijuana Research
Marketwire - Mon Mar 31, 8:04AM CDT
Plandai Biotechnology, Inc. (OTCQB: PLPL) has a real opportunity to advance its medical marijuana research, and in doing so, it could be one of the first publicly traded companies in the cannabis industry to reach clinical trials with the drug. While laws in the US still prohibit the advancement of research using marijuana due to its Schedule 1 classification, Plandai's interest in using the drug to discover promising treatments may be about to come to fruition. The company may owe this unexpected opportunity to relationships it has formed on an entirely different continent.
Plandai Biotechnology expects up to USD2.5m grant from South African Department of Trade and Industry
M2 - Mon May 05, 7:49AM CDT
Botanical extracts company Plandai Biotechnology (OTCQB
LPL) said on Friday that it expects to receive a grant in the range of USD1.3m to USD2.5m from the South African Department of Trade and Industry (DTI). Plandai Biotechnology up for $2.5 Million Grant in Continued Support From South African Government
Marketwire - Fri May 02, 8:02AM CDT
Plandai Biotechnology (OTCQB: PLPL) could soon receive another injection of money from the South African government, and this time it's in the form of a South African Department of Trade and Industry (DTI) grant of between $1.3 - $2.5 million. Plandai originally received $13 million in a government backed loan from the Land and Agriculture Bank, and now the company is eligible for the DTI grant which it has filed the paperwork to be awarded. As Plandai officially opens its production facility in South Africa, the government there remains among the most confident in the company's mission.
Plandai Biotechnology, Inc. Files 10-K/A to Include Re-Audited Financial Statements For Prior Two Years
Marketwire - Thu May 01, 8:03AM CDT
Plandai Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced that on April 29, 2014, the Company filed an amended Form 10-K, which includes the re-audited financial statements for the fiscal years ended June 30, 2012 and 2013. The Company voluntarily elected to re-audit the prior two years in response to the Public Company Accounting Oversight Board ("PCAOB"
revocation of the registration of the Company's prior auditor, Patrick Rodgers, CPA. This revocation did not result from any work performed by Mr. Rogers on behalf of Plandai. On January 22, 2014, Plandai accepted the resignation of Patrick Rodgers from his engagement to be the independent certifying accountant and appointed Terry L. Johnson, CPA, as the Company's independent accountant. Plandai Biotechnology Recruiting Now for Human Clinical Trials to Begin in May
Marketwire - Wed Apr 30, 8:04AM CDT
Plandai Biotechnology (OTCQB: PLPL) has been given the go-ahead to conduct human clinical trials in a 3-month study that will compare the oral bioavailability in the company's Phytofare(TM) Catechin Complex to green tea extracts. In this study, to be conducted at the North West University in Potchefstroom, South Africa, Plandai's 2 technologies, hydrodynamic sheering and Pheroid(R) entrapment, will be put to the test versus a product that hasn't undergone these processes.
Plandai Biotechnology, Inc. Petitions South Africa Department of Health for License to Conduct Cannabis Research
Marketwire - Mon Apr 28, 7:50AM CDT
Plandai Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced it has filed a petition with the Attorney General from the South African Department of Health to obtain a license permitting the company to commence clinical research on the therapeutic and medicinal benefits of cannabis. The petition was made pursuant to Section 22A (9) of the Medicines and Related Substances Act No. 101 of 1965, which provides for pharmaceutical research with cannabis.
OncoSec Medical Appoints New Executive Director of Research and Development
ACCESSWIRE - Tue Apr 22, 10:09AM CDT
OncoSec Medical Inc.'s (OTCQB: ONCS) share volume was strong Apr. 21 with 2,910,820 shares changing hands.
Cannabis Sector Appears To Stabilize With New Advancements - Company Enters JV for 70 Acre Hemp Farm
PR Newswire - Tue Apr 22, 8:02AM CDT
Marijuana companies acquire resources with expansion in sight: Polaris International Holdings, Inc. (OTC: PIHN), Tranzbyte Corporation (OTC: ERBB), Planda (OTC: PLPL), Nuvilex, Inc. (OTC: NVLX), Latteno Food Corp. (OTC: LATF) and MediSwipe, Inc. (OTC: MWIP)
Plandai Biotechnology to begin human bioavailability study of Phytofare against green tea extract in South Africa
M2 - Tue Apr 15, 4:38AM CDT
Plant extracts company Plandai Biotechnology (OTCQB
LPL) disclosed on Monday the receipt of approval to begin a human clinical trial to test the oral bioavailability of its Phytofare Catechin Complex in North West University, Potchefstroom, South Africa. Plandai Biotechnology, Inc. Announces Commencement of Human Bioavailability Study
Marketwire - Mon Apr 14, 10:30AM CDT
Plandai Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced that it has received approval from the Ethics Committee at North West University in Potchefstroom, South Africa to commence a human clinical trial to test the oral bioavailability of its Phytofare(TM) Catechin Complex.
Plandai Biotechnology's Cannabis Extracts Could Further Shape Marijuana Debate
Marketwire - Fri Apr 11, 8:01AM CDT
Plandai Biotechnology (OTCQB: PLPL) has a deal in place to brand and market its future cannabis extracts under the Diego Pellicer Gold label, and it could be those extracts and the company's work with cannabinoids that help shape public opinion in favor of using the drug medicinally. A Pew Research Center survey released last week found that 75 percent of Americans say they feel the legal sale and use of marijuana is inevitable whether they support it or not. While support for marijuana grows, Plandai and its extracts could go a long way toward changing the minds of the drug's opponents.
Plandai Biotechnology, Inc. Qualifies for Grant From South African Department of Trade & Industry
Marketwire - Tue Apr 08, 8:10AM CDT
Plandai Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced that it has qualified for and submitted the necessary paperwork to receive a grant from the South African Department of Trade and Industry (DTI). DTI grants are awarded based on qualifications relating to capital investment in new industry. The Company's extraction and processing factory in the Mpumalanga province in northern South Africa is considered a qualifying facility. DTI representatives will be touring the facility in the first week of May.
Plandai Biotechnology Closer to Unzipping the Magic of Phytofare in New Facility
Marketwire - Fri Apr 04, 7:30AM CDT
Plandai Biotechnology, Inc. (OTCQB: PLPL) welcomes the month of April with a brand new state of the art production facility that is due to be fully operational sometime this month. Plandai recently finished the all-important Stage 2 on the Senteeko Tea Estate in South Africa. It's this section of the factory that CEO Roger Duffield says "the magic of Phytofare" takes place. Plandai will make its money and its mark in the biotechnology sector here as it's where the proprietary hydrodynamic sheering process will takes place.
Plandai Biotechnology, Inc. Commissions Stage 2 of Senteeko Phytofare Factory
Marketwire - Tue Apr 01, 8:03AM CDT
Plandai Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced that it has completed and successfully optimized Stage 2 of its state-of-the-art production facility on the Senteeko Tea Estate in South Africa. Section 2 is the critical stage of the factory's operations as it is in this section that the hydrodynamic sheering process takes place.
Confidential LOI Executed for Unprecedented 'Marijuana Index Fund' - Possible Retracement as The Marijuana Index Dips to $17.95 - 175,000 Jobs Added in February Per US Department of Labor
ACCESSWIRE - Mon Mar 31, 8:09PM CDT
March 31, 2014 / The Marijuana Index - the first and only equity tracking index for marijuana stocks, cannabis stocks, and hemp stocks featuring dynamic financial content, charts, and centralized press for public companies - experienced several significant (positive) events during an otherwise turbulent month (beware the Ides of March, indeed).
Plandai Biotechnology "Waiver" Could Dramatically Expedite Medical Marijuana Research
Marketwire - Mon Mar 31, 8:04AM CDT
Plandai Biotechnology, Inc. (OTCQB: PLPL) has a real opportunity to advance its medical marijuana research, and in doing so, it could be one of the first publicly traded companies in the cannabis industry to reach clinical trials with the drug. While laws in the US still prohibit the advancement of research using marijuana due to its Schedule 1 classification, Plandai's interest in using the drug to discover promising treatments may be about to come to fruition. The company may owe this unexpected opportunity to relationships it has formed on an entirely different continent.
